Evaluating complex neurologic cases often requires unravelling overlapping signs across the central and peripheral nervous systems. Clinicians frequently encounter diagnostic dilemmas when involuntary motor features coexist with cranial neuropathies and neuromuscular weakness. In this clinical scenario, a 55-year-old woman presented with an eight-year progressive history of involuntary choreiform movements, mild ataxia, lower extremity spasticity, external ophthalmoplegia, and skeletal muscle weakness. Consequently, deciphering such a multisystem presentation demands a rigorous clinical reasoning method. Therefore, clinicians must systematically examine each feature to determine whether a unifying condition explains this complex hyperkinetic movement disorder.

Deconstructing the Hyperkinetic Movement Disorder Presentation

Clinicians must first classify involuntary movements using precise phenomenology. In hyperkinetic presentations, phenomenology ranges from chorea and dystonia to myoclonus and tremor. In this patient, continuous, irregular, and flowing involuntary movements suggested adult-onset chorea. However, clinicians must differentiate true choreiform movement from pseudoathetosis caused by proprioceptive sensory loss. Additionally, the examination revealed lower limb spasticity and bilateral extensor plantar responses. These upper motor neuron signs immediately placed lesion localization within the corticospinal pathways. Meanwhile, cerebellar signs, including limb dysmetria and wide-based gait, indicated spinocerebellar pathway involvement. Therefore, the neuroanatomical localization spans the basal ganglia, cerebellar circuits, and descending corticospinal tracts. When adult patients exhibit progressive chorea alongside pyramidal signs, clinicians must look beyond typical isolated basal ganglia pathologies. For instance, Huntington disease typically spares external ocular movements until advanced stages. Neuroacanthocytosis syndromes produce chorea and orofacial dystonia, but they rarely manifest with severe external ophthalmoplegia. Consequently, clinicians who encounter unexplained hyperkinesias must maintain a high index of suspicion for systemic neurodegenerative processes. Ultimately, the combination of widespread central nervous system features alongside ocular motor limitations directs clinical focus toward systemic metabolic, neurodegenerative, or neurogenetic conditions.

Clinical Syndromes Combining Ophthalmoplegia and Myopathy

The simultaneous emergence of external ophthalmoplegia and myopathy substantially narrows the clinical spectrum. Chronic progressive external ophthalmoplegia represents symmetrical, bilateral limitation of ocular motility that typically spares pupillary reactivity. Furthermore, patients often adapt to this restriction by using compensatory head turns rather than reporting frank diplopia. In neuromuscular clinics, progressive external ophthalmoplegia points directly to primary mitochondrial disease or neuromuscular junction failure. For example, ocular myasthenia gravis can mimic external ophthalmoplegia, yet it features prominent diurnal fatigue and fluctuating ptosis. In contrast, the absence of daily fluctuation and poor response to acetylcholinesterase inhibitors argues against autoimmune myasthenia gravis. Moreover, the coexistence of proximal skeletal myopathy confirms widespread muscular pathology. Myotonic dystrophy type 1 and type 2 frequently present with muscle weakness, but clinical and electrical myotonia dominate their physical phenotypes. Additionally, oculopharyngeal muscular dystrophy causes ptosis and dysphagia, but it typically spares generalized coordination and limb reflex physiology. Accordingly, evaluating neuromuscular transmission and intrinsic myofiber pathology remains vital when assessing multi-system extraocular immobility. Thus, chronic external ophthalmoplegia coupled with generalized myopathy, pyramidal spasticity, and hyperkinetic movements provides a classic signature of mitochondrial cytopathy.

Diagnostic Workup and Localization Strategies

A structured diagnostic strategy integrates targeted neuroimaging, biochemical evaluation, and neurophysiological testing. First, magnetic resonance imaging of the brain evaluates structural integrity across the basal ganglia, brainstem, and cerebellum. In complex metabolic disorders, T2-weighted and FLAIR sequences often show symmetrical signal hyperintensities within the deep gray nuclei or profound cerebellar atrophy. Furthermore, magnetic resonance spectroscopy can detect elevated lactate peaks within the basal ganglia or cerebrospinal fluid, supporting cellular energy impairment. Serum creatine kinase testing assesses muscle necrosis, although levels may remain normal or only mildly elevated in metabolic myopathies. Additionally, clinicians should quantify resting serum lactate and pyruvate concentrations, repeating these measurements after standardized exercise testing. Electrodiagnostic studies play a crucial diagnostic role. Electromyography demonstrates low-amplitude, short-duration motor unit action potentials with early recruitment, confirming primary myopathic dysfunction. Conversely, nerve conduction studies exclude sensorimotor polyneuropathy, which frequently complicates spinocerebellar ataxias and mitochondrial disorders. Repetitive nerve stimulation testing differentiates postsynaptic junctional defects from primary muscle pathology. Moreover, muscle biopsy may reveal ragged-red fibers and cytochrome c oxidase deficiency, which provide definitive tissue evidence of respiratory chain disruption. Consequently, objective electrophysiological confirmation of myopathy directs the physician to proceed toward targeted genomic sequencing.

Neurogenetic and Mitochondrial Differential Diagnosis

The intersection of chorea, ataxia, spasticity, external ophthalmoplegia, and myopathy points toward specific neurogenetic conditions. Clinicians must prioritize nuclear and mitochondrial gene mutations governing mitochondrial DNA replication and respiratory chain function. Specifically, mutations in the POLG gene represent a premier diagnostic consideration. POLG variants generate a diverse continuum of phenotypes, encompassing sensory ataxic neuropathy, dysarthria, and ophthalmoplegia, alongside ataxia-neuropathy syndromes and chorea. Furthermore, mutations in TWNK and RRM2B disrupt mitochondrial genome maintenance, causing adult-onset progressive ophthalmoplegia and generalized myopathy. Besides mitochondrial DNA maintenance disorders, spinocerebellar ataxia type 3 and spinocerebellar ataxia type 17 can produce ataxia, spasticity, and hyperkinetic choreiform movements. However, spinocerebellar ataxias do not typically produce prominent fixed external ophthalmoplegia combined with histologically proven skeletal myopathy. Huntington disease-like syndromes and inherited lipid storage diseases like Niemann-Pick type C also merit consideration during diagnostic evaluation. However, Niemann-Pick type C characteristically causes vertical supranuclear gaze palsy rather than true peripheral external ophthalmoplegia. In addition, ruling out acquired autoimmune and paraneoplastic chorea syndromes safeguards patients against erroneous therapeutic assumptions. Therefore, modern comprehensive gene panels utilizing next-generation sequencing or whole-exome sequencing provide the most definitive diagnostic route.

Therapeutic Approach and Long-Term Multidisciplinary Care

Managing multisystem neurogenetic disorders requires an individualized, proactive, and multidisciplinary treatment framework. Currently, disease-modifying genetic therapies remain investigational for most adult mitochondrial and neurodegenerative conditions. Therefore, clinical management emphasizes symptom relief, complication prevention, and functional optimization. Clinicians often manage choreiform movements using vesicular monoamine transporter 2 inhibitors, such as deutetrabenazine or valbenazine, which minimize hyperkinetic motor disruptions. However, physicians must avoid medications that exacerbate mitochondrial dysfunction, notably sodium valproate in POLG-associated disease due to fatal hepatotoxicity risks. Furthermore, physical therapy and occupational therapy mitigate fall risks stemming from ataxia and lower extremity spasticity. Assistive devices maintain independent ambulation while prevent traumatic falls. Ophthalmologists address ptosis using eyelid crutches or surgical repair when severe eyelid droop obstructs visual axes. Additionally, speech and language pathologists must regularly evaluate swallowing mechanics, because coexisting bulbar weakness and ophthalmoplegia increase aspiration risks. Cardiologists should perform serial electrocardiography and echocardiography to screen for subclinical cardiac conduction defects or cardiomyopathy. Consequently, comprehensive counseling regarding prognosis, exercise pacing, and metabolic vulnerability empowers patients and caregivers throughout disease evolution. Ultimately, regular monitoring by a dedicated multidisciplinary medical team optimizes overall independence and preserves motor capability.

How does external ophthalmoplegia help differentiate complex movement disorders?

External ophthalmoplegia selectively narrows the differential diagnosis to neuromuscular junction disorders, mitochondrial cytopathies, and specific genetic spinocerebellar syndromes. While common movement disorders such as Parkinson disease or Huntington disease typically spare external ocular motility, mitochondrial diseases like POLG mutations and progressive external ophthalmoplegia prominently impair extraocular muscle function early in disease progression.

Which laboratory and genetic investigations are most critical for diagnosis?

Clinicians should obtain serum creatine kinase, resting lactate, and comprehensive electrodiagnostic studies to identify underlying myopathy. Following preliminary metabolic screening, clinicians must perform targeted multigene panels or whole-exome sequencing evaluating POLG, TWNK, and spinocerebellar ataxia repeat expansions, which pinpoint the definitive genetic defect without requiring invasive skeletal muscle biopsies.

Why must clinicians avoid sodium valproate in suspected POLG-related disease?

Sodium valproate impairs mitochondrial beta-oxidation and depletes carnitine stores in patients with defective DNA polymerase gamma function. When administered to individuals harboring POLG pathogenic variants, valproate frequently triggers catastrophic, microvesicular hepatic failure and refractory status epilepticus. Therefore, neurologists strictly contraindicate valproate when mitochondrial respiratory chain defects remain under active diagnostic consideration.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Leduc W et al. Clinical Reasoning: A 55-Year-Old Woman With a Hyperkinetic Movement Disorder, External Ophthalmoplegia, and Myopathy. Neurology. 2026 Dec 08. doi: 10.1212/WNL.0000000000218664. PMID: 43013789.
2. Cohen BH, Chinnery PF, Copeland WC. POLG-Related Disorders. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews. Seattle (WA): University of Washington, Seattle; 2018.
3. Mancuso M, McFarland R, Saneto R, et al. Mitochondrial Neuromuscular Disorders: A Clinical Perspective. Lancet Neurol. 2015;14(11):1134-1147.
4. Schaller G, Bega D. Diagnostic Approach to Adult-Onset Chorea and Hyperkinetic Movement Disorders. Continuum (Minneap Minn). 2022;28(5):1354-1378.